CN116602923A — 一种用于关节炎治疗的靶向仿生纳米治疗载体系统
Assigned to First Affiliated Hospital of Jinan University · Expires 2023-08-18 · 3y expired
What this patent protects
本发明的目的是提供一种靶向仿生纳米治疗载体系统,能够携带抗炎物质更准确地识别和调控炎症环境的巨噬细胞,从而实现精准协同抗炎治疗。所提供的靶向仿生纳米治疗载体系统,是由磷脂、活性氧响应性芳基硼酸酯修饰磷脂酰丝氨酸(BPS)、胆固醇和助剂构成的纳米脂质体;所述的抗炎物质,为疏水性抗炎物质或亲水性抗炎物质。本发明中制备靶向仿生纳米脂质体系统易于携带抗炎物质,避免正常生理环境中单核巨噬细胞系统清除,而在关节炎部位炎症环境中发生模拟细胞凋亡的转变,从而实现针对关节炎部位巨噬细胞的靶向协同抗炎治疗。
USPTO Abstract
本发明的目的是提供一种靶向仿生纳米治疗载体系统,能够携带抗炎物质更准确地识别和调控炎症环境的巨噬细胞,从而实现精准协同抗炎治疗。所提供的靶向仿生纳米治疗载体系统,是由磷脂、活性氧响应性芳基硼酸酯修饰磷脂酰丝氨酸(BPS)、胆固醇和助剂构成的纳米脂质体;所述的抗炎物质,为疏水性抗炎物质或亲水性抗炎物质。本发明中制备靶向仿生纳米脂质体系统易于携带抗炎物质,避免正常生理环境中单核巨噬细胞系统清除,而在关节炎部位炎症环境中发生模拟细胞凋亡的转变,从而实现针对关节炎部位巨噬细胞的靶向协同抗炎治疗。
Drugs covered by this patent
- Camptosar (Irinotecan Hydrochloride) · Pfizer
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.